Arcturus Therapeutics Holdings Inc. ARCT
8.44 USD -0.87 (-9.34%)
At closeNov 13, 2026, 6:12 AM EST
8.30 -0.14 -1.66%
Pre-market · Nov 13, 6:12 AM ET
8.42 Day range 9.06
5.50 52-week range 17.96
- YTD
- +37.68%
- 1 year
- +3.81%
News
benzinga.com Arcturus Therapeutics Q3 2026 Earnings Call Transcript Arcturus Therapeutics (NASDAQ:ARCT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Arcturus Therapeutics Q3 EPS $(0.26) Beats $(0.68) Estimate, Sales $18.297M Beat $7.998M Estimate Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.68) by 61.76 percent. This is a 46.94 percent increase over losses…
benzinga.com Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs.…
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
benzinga.com CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.
benzinga.com Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19 Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
benzinga.com Why Is Arcturus Therapeutics Stock Gaining Thursday? Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
benzinga.com Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20 Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.
benzinga.com Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
benzinga.com BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20 BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.
benzinga.com Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
benzinga.com Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study Arcturus Therapeutics Holdings Inc. ((the "Company, " "Arcturus, NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced…- benzinga.com Arcturus To Acquire myNEO, An AI Discovery Company, To Improve mRNA Design Quality, Accelerate Innovation, And Enhance Target Identification Capability; No Financial Terms Disclosed; Co To Host Presentation At 4:30 p.m. ET today Arcturus to Acquire myNEOArcturus has entered into a definitive agreement to acquire myNEO, subject to customary closing conditions. The transaction is expected to close in October. Arcturus has been…
- benzinga.com Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0 ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 studyLUNAR 2.0™ produces greater than 30-fold higher protein…
- benzinga.com Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23 Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today
benzinga.com National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rose, while National Beverage and several stocks fell premarket after disappointing results, led by Zumiez down 15.7%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million. Jupiter Neurosciences…
benzinga.com Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED) Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2…
- benzinga.com Arcturus Therapeutics Q2 EPS $(0.84) Beats $(1.00) Estimate, Sales $2.959M Miss $3.199M Estimate Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.00) by 16 percent. This is a 147.06 percent decrease over losses of…
- benzinga.com Arcturus Therapeutics To Present At Canaccord Annual Growth Conference August 11 Webcast link can be found under Investor Relations/Events section of Arcturus’ website.
benzinga.com Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
benzinga.com This Adobe Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about these stocks. Photo via Shutterstock.
benzinga.com This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consider buying HONA stock - analysts' thoughts.- benzinga.com Arcturus Therapeutics Collaborates With Thermo Fisher Scientific To Help Support Phase 3 Development And Potential Commercialization Of ARCT-032, Investigational mRNA Therapy For Cystic Fibrosis Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rightsArcturus Therapeutics Holdings Inc. (("Arcturus", NASDAQ:ARCT), a messenger RNA medicines company…
- benzinga.com Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27 Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $27.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Arcturus Therapeutics Q1 EPS $(0.95) Beats $(1.00) Estimate, Sales $2.061M Miss $7.233M Estimate Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.00) by 5 percent. This is a 82.69 percent decrease over losses of…
benzinga.com This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.
benzinga.com This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday Wall Street analysts upgraded top stocks, including Chipotle, ARM, BP, and Solaredge. See what they think about buying BP stock.
benzinga.com This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday 
benzinga.com This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy rating, $88 PT. See analyst ratings.
benzinga.com This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday Top Wall Street analysts upgraded Carnival Corp, Tandem Diabetes Care, and Union Pacific Corp. Analysts see potential in UNP stock.
benzinga.com This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts have changed their outlook on top names, with new coverage and price targets. See the latest analyst ratings and opinions.- benzinga.com B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22 B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $22.
benzinga.com Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews 
benzinga.com Citigroup Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $21 Citigroup analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $66 to $21.
benzinga.com Citigroup Maintains Neutral on Arcturus Therapeutics, Raises Price Target to $8 Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and raises the price target from $7 to $8.- benzinga.com Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $25 Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $72 to $25.
benzinga.com Arcturus Therapeutics Q4 Earnings Assessment 
benzinga.com Earnings Scheduled For March 3, 2026 
benzinga.com Earnings Preview: Arcturus Therapeutics 
benzinga.com Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $7 Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $9 to $7.- benzinga.com Arcturus Therapeutics Holdings Files For Mixed Shelf Of Up To $500M Common StockPreferred StockDebt SecuritiesWarrantsRightsUnits__________________________From time to time, we may offer and sell up to an aggregate of $500,000,000 of any combination of the securities…
- benzinga.com Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9 Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.
- benzinga.com Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $72 Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $140 to $72.
- benzinga.com HC Wainwright & Co. Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9 HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.
- benzinga.com Arcturus Therapeutics Q3 EPS $(0.49) Beats $(0.90) Estimate, Sales $17.151M Miss $21.196M Estimate Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.90) by 45.49 percent. This is a 88.46 percent decrease over losses…
benzinga.com Earnings Scheduled For November 10, 2025